Innealta Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

Innealta Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,386	Closed	-$236K	–	82
2025 Q4	$236K	Buy	+1,386	New	+$212K	0.13%	66

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Innealta Capital's JAZZ Position: Q1 2026 in Review

Innealta Capital sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2026, closing a stake of 1,386 shares — an estimated $236K sold.

Innealta Capital first reported a position in JAZZ in Q4 2025 and held it in 1 quarter. The position peaked at $236K in Q4 2025. 571 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

Innealta Capital reported no remaining Jazz Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Innealta Capital sold 1,386 Jazz Pharmaceuticals shares in Q1 2026, an estimated $236K.
Innealta Capital first reported a position in Jazz Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Innealta Capital's Jazz Pharmaceuticals position peaked at $236K in Q4 2025.
571 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Innealta Capital's 13F filing for Q1 2026, filed 4 May 2026.